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Abstract
 The COVID-19 pandemic is responsible for increasingBackground:
deaths globally. Most estimates have focused on numbers of deaths, with
little direct quantification of years of life lost (YLL) through COVID-19.  As
most people dying with COVID-19 are older with underlying long-term
conditions (LTCs), some have speculated that YLL are low. We aim to
estimate YLL attributable to COVID-19, before and after adjustment for
number/type of LTCs.
 We first estimated YLL from COVID-19 using standard WHO lifeMethods:
tables, based on published age/sex data from COVID-19 deaths in Italy.
We then used aggregate data on number/type of LTCs to model likely
combinations of LTCs among people dying with COVID-19. From these, we
used routine UK healthcare data to estimate life expectancy based on
age/sex/different combinations of LTCs. We then calculated YLL based on
age, sex and type of LTCs and multimorbidity count.
 Using the standard WHO life tables, YLL per COVID-19 deathResults:
was 14 for men and 12 for women. After adjustment for number and type of
LTCs, the mean YLL was slightly lower, but remained high (13 and 11 years
for men and women, respectively). The number and type of LTCs led to
wide variability in the estimated YLL at a given age (e.g. at ≥80 years, YLL
was >10 years for people with 0 LTCs, and <3 years for people with ≥6).
 Deaths from COVID-19 represent a substantial burden inConclusions:
terms of per-person YLL, more than a decade, even after adjusting for the
typical number and type of LTCs found in people dying of COVID-19. The
extent of multimorbidity heavily influences the estimated YLL at a given
age. More comprehensive and standardised collection of data on LTCs is
needed to better understand and quantify the global burden of COVID-19
and to guide policy-making and interventions.
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Introduction
When severe, coronavirus disease 2019 (COVID-19) causes 
acute respiratory failure, often requiring mechanical ventilation1. 
Globally, as of 6th April 2020, more than 1,200,000 confirmed 
cases have been reported including 67,000 deaths2. In response 
to this threat, governments have introduced non-pharmaceutical 
interventions such as physical distancing and the delivery of 
health services has radically changed, with resources diverted 
towards the management of COVID-19 and away from their 
usual activities3. These measures have aimed to limit a surge in 
cases that risks overwhelming healthcare services4.
Since few health care systems could have responded adequately 
to the increased need for acute care without these changes, these 
decisions were in some ways inevitable. However, in the absence 
of a vaccine, as societies seek to “return to normal”, decisions 
about the extent and nature of ongoing measures to limit spread 
of COVID-19 will be more difficult. These choices will require 
balancing the likely direct effects on mortality from COVID-19 
against the likely indirect impacts on mortality for other conditions 
– due, for example, to inadequate access to necessary services 
for many people with long-term conditions (LTCs), potential 
reluctance of the public to attend for acute events such as 
myocardial infarction, or impacts from forced unemployment, 
loss of income and social isolation. The indirect effects are likely 
to be complex, most will be downstream, and will require exten-
sive research to be better understood. However, we need to capture 
the direct effects of COVID-19 as accurately as possible now, via 
currently available data and methodologies.
Currently, most reports of COVID-19 deaths have used raw 
counts2. This may give a distorting picture of the mortality bur-
den, however, as it does not consider how long someone who died 
from COVID-19 might otherwise have been expected to live. As 
people dying from COVID-19 are predominantly older and have 
pre-existing LTCs5–7, some have speculated that many of these 
people would have soon died of other causes and that life 
expectancy may therefore not being greatly impacted8,9. While 
multimorbidity, the presence of multiple LTCs, is known to be 
associated with increased mortality10, people with multimorbidity 
nonetheless can be expected to live for many years11. Raw counts 
of deaths may therefore mislead policy-makers and the public, 
causing them to either over- or under-estimate the total impact 
of COVID-19 related deaths.
Within epidemiology, there is a standard measure used to account 
for this difficulty, the years of potential life lost (YLL)12. YLL 
can be expressed per-capita as the average number of years an 
individual would have been expected to live had they not died 
of a given cause. The conventional approach to YLL uses data 
on the age at which deaths occurred combined with typical life 
expectancy at a given age, to estimate a weighted average of the 
number of years lost. YLL is used to allow fair comparisons of 
the health impact of different policies, such as different meas-
ures to address the pandemic. However, given the controversial 
role of multimorbidity in COVID-19 deaths it is also important 
to calculate YLL additionally considering the effects of the 
presence of a single LTC or multimorbidity.
Therefore, we propose to quantify the burden of mortality related 
to COVID-19, both using the conventional age-based YLL 
measure, and YLL additionally accounting for type and number 
of underlying LTCs.
Methods
WHO standard YLL approach
The standard approach for calculating years of life lost is to 
apply the distribution of ages among those who died from a 
specific cause to a standard life-table. For the purposes of inter-
national comparison, we opted to use the WHO 2010 Global 
Burden of Diseases table as the reference13, which presents YLL 
by age, but not by sex or extent of multimorbidity. This method 
involves summing the expected years of life remaining from 
the table according to the number (or for the mean YLL the 
proportion) of people dying within each age-band. We applied 
the age distribution of COVID-19 deaths in Italy from published 
data to estimate the YLL.
Overview of modelling to accommodate long-term conditions 
and multimorbidity
The remainder of the methods describes our approach to 
estimating YLL accounting for number and type of underlying 
LTC, along with age and sex. Our modelling comprised three 
main components: (i) estimating the prevalence of, and corre-
lations between, LTCs among people dying with COVID-19; 
(ii) modelling UK life expectancy based on age, sex, and each com-
bination of these LTCs separately; and (iii) combining these models 
to calculate the estimated YLL per death with COVID-19. These 
are summarised by age-group, sex, and multimorbidity counts 
(that take into account different combinations of LTCs).
The data sources used for each of these stages of modelling are 
summarised in Figure 1.
Rapid review
To inform our estimates of number and type of LTCs, we 
performed a rapid review to identify data on underlying condi-
tions for people dying with COVID-19. We searched the WHO 
repository of COVID-19 studies on 24th March 2020. To identify 
studies reporting data on LTCs among people who had died 
from Covid-19, we screened titles and abstracts of all epidemio-
logical, clinical, case-series and review articles (n=1685). We 
identified and screened 77 potentially relevant full-text articles, of 
which four reported aggregate data on LTCs among people who 
had died of COVID-19. Three were small studies (32, 44, and 
54 deaths, respectively) based in Wuhan, China5–7. However, the 
fourth was a comprehensive report from the Istituto Superiore di 
Sanità (ISS) (published each Tuesday and Wednesday) includ-
ing data on 11 common LTCs (ischaemic heart disease, atrial 
fibrillation, heart failure, stroke, hypertension, diabetes, dementia, 
chronic obstructive pulmonary disease, active cancer in the past 5 
years, chronic liver disease and chronic renal failure), as well as 
the number of patients who had 0, 1, 2 or ≥3 LTCs for 701 of the 
6801 people who died with COVID-19 in Italy14. In view of the 
smaller sizes of the Chinese studies, and the greater dissimilar-
ity of these populations with the UK relative to the Italian data, 
we opted not to include these in the analysis. These data were 
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Figure 1. Overview of components of models. Green boxes indicate source of data/final outputs. Yellow boxes indicate Istituto Superiore di 
Sanità (ISS) data and blue boxes indicate Secure Anonymised Record Linkage (SAIL) data. White boxes indicate each model used to inform 
the final analysis. AGG - aggregate. IPD - individual level patient data.
used to construct a plausible scenario for the prevalence of 
combinations of LTCs among people who died from COVID-19 for 
the modelling presented here.
Long-term condition prevalence and correlation models. This 
first stage of our modelling aimed to estimate the prevalence 
and correlation between specific LTCs among people dying with 
COVID-19.
We utilised aggregate data on COVID-19 deaths from the Istituto 
Superiore di Sanità in Italy. Since we were unable to obtain IPD 
for the Italian case-series of deaths from COVID-19, we had 
to infer the joint prevalence of LTCs from the summarised 
information available, i.e. the marginal distribution of multimor-
bidity counts (the row sums, or total number of diseases for each 
patient, wherein counts of ≥3 LTCs were collapsed into the single 
category of 3+) and the marginal distributions of LTC frequency 
(the columns sums, or the total number of patients with each 
LTC). To that end, we developed a Bayesian latent process model 
of disease prevalence and correlation and fitted it using Markov 
chain Monte Carlo (MCMC) to both elements in the published 
data. This analysis was applied jointly to the small number of 
deaths that had occurred in Scotland, primarily to aid convergence 
in Bayesian model fitting by providing some information about 
the correlation between LTCs15. The Scottish subset of the data 
contained a partial record of known LTCs for individual patients, 
but the multimorbidity count per patient, as well as the marginal 
frequency of each LTC, were missing (hence, modelled as 
latent). Bayesian priors for the correlations between diseases 
were specified with a tendency to zero (shrinkage). Numerical 
investigations indicated little sensitivity of convergence to the 
strength of shrinkage, so we opted for weak shrinkage as a 
precautionary approach. This model gave us the full matrix of 
correlations between every combination of LTCs at the level of 
individuals, therefore providing us with a complete dependence 
structure of LTCs presented within the sample of COVID-19 
mortalities. In order to propagate uncertainty through the 
analysis, from this fitted model (effective sample size of 
MCMC 410) we simulated 10,000 notionally “typical” patients, 
with plausible combinations of LTCs (under the combined 
Italian and Scottish data).
To test the sensitivity of our findings to the estimated correla-
tions, we also estimated the YLL under two opposite extremes 
(i) that LTCs were independent and (ii) that LTCs were highly 
correlated. Unlike the Bayesian LTC mode, these sensitivity 
analyses did not use the information on the multimorbidity 
counts from the ISS report, but only the proportion of patients 
with each of the eleven comorbidities. For the “independent” 
scenario we created 11 vectors comprising 1s and 0s (respec-
tively with and without the long term condition) corresponding 
in length to the number of patients. We then sampled from these 
vectors with replacement to obtain 10,000 simulated patients. For 
the “highly correlated” scenario we first sorted each vector, then 
combined them to form a 710x11 matrix, then sampled each row 
with replacement to obtain 10,000 simulated patients.
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Age models. Next, we modelled the relationship between age 
and multimorbidity counts among people dying with COVID-19. 
We were unable to obtain direct estimates of the association 
between age and extent of multimorbidity among patients who 
had died from COVID-19. Therefore, we modelled two scenarios: 
independence between age and multimorbidity count (i.e. no 
correlation between age and multimorbidity count among people 
dying of COVID-19), and a positive association between age and 
multimorbidity count. To inform the latter, we examined data 
within SAIL for 145 patients who had influenza recorded as the 
cause of death in their death certificate in 2011. We found that for 
men, age increased by 4.7 years per unit increase in the number of 
LTCs until the count reached 6 after which there was no evidence 
of further increase. For women, the figure was 2.6. Therefore, we 
performed the modelling assuming that for COVID-19 the mean 
age increased by 5 years per unit increase in multimorbidity count 
across the range from 0 to 6 LTCs in men. To allow for some degree 
of uncertainty around this estimate by sampling from a normal 
distribution. We arbitrarily chose a standard deviation of 0.5. We 
estimated this similarly for women, but using a mean increase 
of age of 3 years per increase in multimorbidity count. We 
incorporated this information in a model fitted to the summary 
age data provided in the Italian case report. We obtained 10,000 
samples from the posterior distribution for inclusion in the 
YLL calculations. SAIL analyses were approved by SAIL 
Information Governance Review Panel (Project 0830). Approval 
for the use of individual patient data in the analysis was given 
by the NHS Public Health Scotland Caldicott officer.
Survival models. For patients aged 50 years or older at death, we 
estimated mortality according to age, sex and combinations of 
each LTC using the Secure Anonymised Information Linkage 
(SAIL) databank. SAIL is a repository of routinely collected 
healthcare data (including primary care, hospital episodes, and 
mortality data) from a representative sample covering approxi-
mately 70% of the population of Wales. From these data, we 
identified all participants aged over 49 years who were registered 
with a participating practice for the duration of 2011 (approxi-
mately 0.85 million people). This period was selected as electronic 
coding of diagnoses was well established, and it allowed >6 years 
of follow-up. Age and sex were extracted from primary care 
records. We also identified all LTCs for which we had informa-
tion of COVID-19 deaths from Italy. LTCs were identified using a 
combination of primary care data (using Read diagnostic codes) 
and hospital episodes (using ICD-10 codes). Individuals were 
considered to have a LTC if they had a relevant diagnostic code 
entered prior to 31st December 2011. Relevant codes were 
identified from the Charlson comorbidity index and the 
Elixhauser comorbidity index16,17, which had established 
algorithms for identification from ICD-10 codes18, and have 
been adapted for using Read codes in primary care19. Code lists 
are available in the supplementary material15.
All-cause mortality was assessed by linkage to national mortality 
registers from 1st January 2012 until August 2018 (last available 
data). Participants were censored if they de-registered from a 
participating SAIL practice. We used the flexsurv package in 
R (version 1.1.1) to fit a Gompertz model treating age as the 
timescale20. We assessed the fit of this distribution graphically 
(supplementary material)15. In models stratified by sex we included 
all the LTCs as main effects as well as age-LTC interactions 
that improved the model fit in terms of the Akaike information 
criterion. In sensitivity analyses we also included two-way 
(comorbidity-comorbidity) and three-way (comorbidity-
comorbidity-age) interaction terms for the four comorbidities 
with the largest effect measure estimates (COPD, heart failure, 
liver failure and dementia) requiring 12 additional parameters. 
To propagate uncertainty from the survival models we obtained 
10,000 samples of the coefficient estimates by sampling from a 
multivariate normal distribution corresponding to the coefficients 
and variance-covariance matrix from the regression models.
Combination of comorbidity and mortality models. In the final 
analysis, we combined 10,000 samples from all three sources: LTC 
combination models, age models and survival models. We used 
the rate and shape parameters with the cumulative distribution 
function implemented in the flexsurv package to calculate the 
survival probabilities at 3-month intervals from aged 50 to 
120 (to allow all curves to descend to zero). From these times 
and survival probabilities we estimated the mean survival, or 
life expectancy.
Bayesian models were written in the JAGS language21 and 
implemented using runjags for R (version 2.0.4)22, survival models 
were fit using the flexsurv package in R (version 1.1.1)20, and for 
the final analysis the model-outputs were also combined in 
R (version 3.6.1). The 95% uncertainty intervals were obtained 
using empirical bootstrapping, with the number of samples in the 
mean equal to the effective sample size from the LTC correlation 
model. All code, data (except individual-level data for Scotland), 
intermediate outputs and diagnostic plots are provided on 
GitHub (https://github.com/dmcalli2/covid19_yll_final)15.
Results
WHO life tables
The proportion of men and women in 10-year age-bands was 
reported for the 6801 deaths included in the ISS case report. On 
applying the proportion in each age-band to the WHO Global 
Burden of Disease 2010 life tables for men, we found that the 
YLL was 14.4 per person using the whole cohort and 14 after 
excluding those aged under 50. For women, comparable figures 
were 12.2 and 11.8 years, respectively.
Comorbidity models
For 710 patients who had died with COVID-19 for whom 
information on LTCs was presented in the ISS report14, the 
proportion with each LTC was as follows:- ischaemic heart 
disease 27.8%, atrial fibrillation 23.7%, heart failure 17.1%, stroke 
11.3%, hypertension 73%, diabetes 31.3%, dementia 14.5%, 
chronic obstructive pulmonary disease 16.7%, active cancer in 
the past 5 years 17.3%, chronic liver disease 4.1%, chronic renal 
failure 22.2%. The ISS report also presented the proportion of 
patients who died with each of the following multimorbidity 
counts: 0 (2.1%), 1 (21.3%), 2 (25.9%) and ≥3 (50.7%). Using 
these data, alongside individual-level patient data for a small 
number of patients from Scotland to aid with model fitting, 
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we were able to simulate a set of realistic notional patients 
with specific combination of LTCs. The correlations between 
every pair of LTCs are shown in the appendix and the full 
posterior distributions from the modelling are available at GitHub 
(https://github.com/dmcalli2/covid19_yll_final)15.
Age models
Based on the proportions reported for each age-band, for men 
the mean age for the ISS deaths was 77.9 years when people 
aged less than 50 were excluded and 77.4 years overall. For 
women the figure was 81.1 for both. The models we fit to these 
data to smooth out the distribution and to make it easier to 
accommodate different scenarios for the association between 
age and multimorbidity counts comorbidity are shown in 
Figure 2; the distribution of age and multimorbidity counts 
for men and women are shown under the assumption that 
these are independent, and under the assumption that multimorbid-
ity is associated with age.
Survival models
The coefficients for the survival models are shown in the 
supplementary appendix. Briefly, all LTCs other than hypertension 
were associated with increased mortality (in a model including 
10 other LTCs), and for each LTC the association with mortality 
was attenuated as the baseline age increased. Figure 3 shows the 
survival curves applied to different age and combinations of LTCs, 
stratified by age-band and multimorbidity count. This figure shows 
how these associations and age relate to survival across the age 
range from 50 to 110 years old.
Years of life lost
For men the average YLL on adjusting for number and type of 
LTC as well as age was 13.1 (12.2–14.1). For women this value 
was 10.5 (9.7–11.3). The results were similar under the different 
assumptions for the age-multimorbidity association and in both 
sensitivity analyses, whether assuming strongly correlated or 
independent LTCs (Table 1). For comparison, the YLL based on 
age alone using the WHO tables was 14.0 and 11.8 for men and 
women, respectively.
Across the simulated patients there was substantial variation in 
YLL adjusted for multimorbidity count (Figure 4).
On stratifying the YLL estimates by sex, age and multimorbidity 
count (for the simulated patients) there were clear differences 
(Figure 5, Table 2) with the YLL ranging from around 2-years 
per person in men or women aged 80 with large numbers of LTCs, 
to around 35 years in younger people without any LTCs (Table 2). 
For most age-bands and most multimorbidity counts the YLL 
per person remained above 5. In sensitivity analyses including 
the survival models with additional comorbidity-comorbidity and 
comorbidity-comorbidity-age interaction terms, (despite these 
models having a better fit based on AIC) than the model presented 
here, the YLL only changed minimally from that seen in the 
main analysis. This was true overall YLL for each sex (13.1, 95% 
CI 12.2–14.0 and 10.5; 95% CI 9.7–11.3 for men and women 
respectively) and on additionally stratifying on age and multi-
morbidity count (as shown in Table 2). For the latter comparison, 
Figure 2. Modelled distribution of age in ISS population, assuming age is associated with comorbidity counts, and assuming age 
and comorbidity are independent. Coloured bars indicate the comorbidity count from zero (dark/blue) to 11 (light/yellow).
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Figure 3. Survival curves for all-cause mortality. Figures are paneled by age and sex. Individual lines represent survival curves for a single 
simulated patients with a given set of LTCs. From light to dark (yellow to blue) they show decreasing multimorbidity counts. There are 10, 000 
lines, one for each notional patient. Lines run from the age at which each simulated patient died (survival probability = 1) to when they would 
have died under the model (survival probability = 0). Patients with the same age and total multimorbidity count will have a different survival 
curve if they have a different set of 11 LTCs.
Table 1. Years of life lost (YLL) and 95% credible intervals under 
different modelling assumptions.
LTC-LTC 
correlation
Age-multimorbidity 
correlation
Men Women
Modelled Associated 13.1 (12.2-14.1) 10.5 (9.7-11.3)
Modelled Independent 11.2 (10.6-11.9) 9.1 (8.5-9.7)
Independent Associated 12 (11.2-12.7) 9.9 (9.2-10.5)
Independent Independent 11.5 (10.9-12.1) 9.5 (8.9-10.1)
Highly 
correlated
Associated 13.3 (12.4-14.3) 10.9 (10.1-11.8)
Highly 
correlated
Independent 12.9 (12.1-13.6) 10.5 (9.8-11.3)
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Figure 5. YLL stratified by sex, age and multimorbidity count. Coloured bars indicate the multimorbidity count from zero (dark/blue) to 11 
(light/yellow).
Figure 4. YLL by sex. Coloured bars indicate the multimorbidity count from zero (dark/blue) to 11 (light/yellow).
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the largest difference – 0.7 YLL – was seen in women aged 50–59 
with six comorbidities. For most age-comorbidity bands the YLL 
was the same, to one decimal place, under both survival models.
Discussion
Summary of main findings
Using published data on people who have died from COVID-19 
and survival models based on age and multimorbidity count in 
a general population in the United Kingdom, we estimated the 
burden (years life lost) from COVID-19 related mortality. We 
make a number of important observations. First, using the WHO 
GBD 2010 life tables as the reference13, the estimated YLL was 
over a decade for COVID-19 deaths with 14 YLL in men and 
12 in women. As such, mortality from COVID-19 represents a 
substantial burden to individuals and comparable to high burden 
LTCs such as ischaemic heart disease and chronic obstructive 
pulmonary disease. Second, YLL estimated from models using 
the prevalence of underlying LTCs based on patients dying from 
COVID-19 in Italy and age-, sex- and multimorbidity count- 
specific survival models in the UK did not drastically impact the 
YLL. Across both men and women, the number of YLL dropped 
to 13 and 11 years respectively. Third, across most age and 
multimorbidity count strata the estimated YLL per person 
remained substantial and generally above 5 years. This means 
that even after accounting for multimorbidity count, most indi-
viduals lost considerably more than the “1–2 years” suggested by 
some commentators23 perhaps reflecting the high prevalence of 
multimorbidity in this population, especially in those over the 
age of 50 years24,25. Finally, whilst the YLL remained high across 
most age- and multimorbidity count strata, the presence of 
multimorbidity did indeed influence the magnitude of the YLL. 
For example, in the elderly, over the age of 80, the estimated 
YLL in people with no LTCs was 11 years falling to less than two 
years with an increasing multimorbidity count.
YLL is a widely used metric to compare the relative impact of 
different causes of death and is used to guide policy-making and 
health service delivery and to prioritise interventions aimed at 
preventing deaths26. Using UK reports for approximate 
comparisons, the YLL for other conditions ranged, per capita 
from 8.2 for chronic obstructive pulmonary disease, 11.6 
for coronary heart disease, 13.1 for pneumonia, and 21.6 for 
asthma27. Therefore, against these benchmarks, mortality from 
COVID-19 represents a substantial burden to individuals.
The estimated YLL can vary substantially depending on the 
reference population chosen and the age distribution among 
those who die. Moreover, where attempts are made to account 
for underlying conditions in those who died, the accuracy will 
depend on the quality and completeness of data both for those 
deaths, and in the reference population used to obtain estimates 
of survival according to those underlying conditions. Nonetheless, 
although imperfect, we would argue that public health agencies 
should present estimates of YLL for COVID-19, alongside the more 
usual counts of deaths. We have already seen that if agencies do 
not do so, commentators can and will fill this vacuum, sometimes 
making substantial errors such as using life expectancy at birth to 
make inferences about the years of life lost by someone who has 
already lived into later life and thereby considerably underestimat-
ing the impact of the disease on individuals23.
Strengths and limitations
Our analysis is novel in that it adjusts YLL for the number and 
type of underlying LTCs. This is important as people with under-
lying multimorbidity are recognised to be more vulnerable to 
COVID-19. However, although we had data for eleven common 
and important LTCs, we did not have markers of underlying 
disease severity among those who died. Severity of the underly-
ing LTC has considerable impact on life expectancy28. Moreover, 
Table 2. Mean years of life lost, accounting for type of long-term conditions, by 
age-band, sex and multimorbidity count.
Men Women
Multimorbidity 
count
50-59 60-69 70-79 80+ 50-59 60-69 70-79 80+
0 35.81 26.78 18.43 11.02 35.28 25.50 17.70 10.42
1 35.03 26.09 17.58 10.05 34.83 25.59 17.13 8.92
2 29.67 22.07 14.72 8.15 29.06 21.35 14.20 7.19
3 25.01 19.05 12.50 6.59 26.27 18.08 11.98 5.85
4 23.55 16.28 10.64 4.95 20.44 15.58 9.97 4.52
5 19.39 13.43 8.61 3.51 16.88 11.61 8.23 3.54
6 - 6.24 7.04 2.42 17.67 10.09 6.44 2.70
7 - 7.99 6.32 2.03 - 7.96 4.83 2.32
8 - 6.60 4.79 1.65 - 6.23 3.94 1.85
9 - 5.97 3.95 1.40 - - 3.04 1.58
10 - - 2.62 1.17 - 2.81 2.55 1.22
11 - - - 1.40 - - 2.05 1.20
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we had no data for rarer severe LTCs, which may nonetheless 
be common among those who die from COVID-19 at younger 
ages. As such, the attenuation of YLL following adjustment 
for LTCs may be an underestimate. However, we think that this 
effect is unlikely to be substantial enough to reduce YLL to the 
orders of magnitude suggested by some commentators. Indeed, 
on stratifying by age and multimorbidity counts, we rarely 
found average YLLs of below three. Also, we were not able to 
adjust our estimates for other factors and exposures (such as 
socioeconomic status, occupation, smoking, health behaviours) 
which would have given a more accurate representation of life- 
expectancy in the absence of COVID-19.
We did not have access to large quantities of individual-level 
data with which to estimate the prevalence of different combina-
tions of LTCs. Therefore, we fitted a complex model (which was 
methodologically innovative and will be the subject of a separate 
publication) to estimate the joint probabilities, using the overall 
(marginal) estimates of each LTC, and the overall multimorbid-
ity counts alongside a small amount of individual-level data from 
Scotland to help with model fitting. This model did not fully 
converge and had wide posteriors (indicating substantial uncer-
tainty) for the correlation between LTCs. We nonetheless included 
the results of this model in our analysis because (i) it represents 
the best estimate for the joint probabilities given the available 
data and importantly, (ii) the results for overall YLL remained 
substantially similar in widely different sensitivity analyses 
assuming either that LTCs are highly correlated among people 
dying from COVID-19 or that they are entirely independent.
Finally, given the emergent nature of the coronavirus pandemic, 
this study was conducted rapidly and under pressure of time. We 
chose the best data for age, sex and prevalence of LTCs that was 
available to us at the time of our modelling, but better-quality 
individual-level data specific to individual countries will yield 
substantially more reliable estimates. We would suggest that each 
public health agency should produce country-specific estimates, 
using the same LTC definitions in those who died as in the 
reference population and ideally to an agreed international 
protocol. Our study has used complex state-of-the-art statistical 
modelling and inference techniques, which rely on expensive 
computer simulations. Given the time constraints, we had to find 
an acceptable trade-off between estimation accuracy and time 
constraints. Therefore, we will continue to refine our work to 
improve the convergence of the numerical procedures, although 
we do not expect that our conclusions, either about the overall 
YLL per capita, or about the distribution of YLL within the pop-
ulation, will substantially change. We have also provided all our 
data (except individual-level data form the Scottish population, 
for which we provide a simulated substitute dataset) and code 
to allow others to check our modelling and correct any errors15.
Conclusion
Among patients dying of COVID-19, there appears to be a 
considerable burden in terms of years of life lost, commensurate 
with diseases such as coronary heart disease or pneumonia. 
While media coverage of the pandemic has focused heavily on 
COVID-19 affecting people with ‘underlying health conditions’, 
adjustment for number and type of LTCs only modestly reduces 
the estimated YLL due to COVID-19 compared to estimates 
based only on age and sex. Public health agencies and govern-
ments should report on YLL, ideally adjusting for the presence 
of underlying LTCs, to allow the public and policy-makers to better 
understand the burden of this disease.
Data availability
All code, data (except individual-level data for Scotland), inter-
mediate outputs and diagnostic plots are provided on GitHub: 
https://github.com/dmcalli2/covid19_yll_final.
Source data
Zenodo: Data and Code to support COVID-19 - exploring the 
implications of long-term condition type and extent of multi-
morbidity on years of life lost: a modelling study. https://doi.org/ 
10.5281/zenodo.375156129.
This project contains the source data used in performing this 
modelling study (except individual-level data for Scotland), 
which are also available via GitHub (https://github.com/dmcalli2/
covid19_yll_final/tree/master/Data).
Individual-level data for Scotland are accessible via application 
to the electronic Data Research and Innovation Service (eDRIS) 
and the Public Benefit and Privacy Panel (PBPP) (https://www.
isdscotland.org/Products-and-Services/EDRIS/). Individual-level 
data for Wales are available via application to the Secure Ano-
nymised Information Linkage (SAIL) at https://saildatabank.com/. 
For both eDRIS and SAIL, individuals are required to complete 
information governance training, be affiliated with an appropri-
ate organisation (e.g. a university, healthcare organisation, etc.) 
complete an application form, and the analysis must be performed 
to support research conducted in the public interest.
Extended data
Zenodo: Data to support COVID-19 - exploring the implications 
of long-term condition type and extent of multimorbidity on 
years of life lost: a modelling study. http://doi.org/10.5281/ 
zenodo.375156129.
This project contains the archived scripts used during this model-
ling study, which are also available via GitHub (https://github.com/
dmcalli2/covid19_yll_final/tree/master/Scripts).
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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 Comments on this article
Version 1
Reader Comment 03 May 2020
, Other, USA, USAJason Blumberg
I’m perplexed by this study. How can it be assumed that the Covid victims would have lived the average
life expectancy unless there’s no or minimal standard deviation around that average? Wouldn’t it be more
compelling to compare to the minimum life expectancy of each cohort? Otherwise, you are implicitly
assuming that the people who are dying are more or less representative of the average, which seems like
a major assumption that, if untrue, would render your conclusions pretty useless. I hope I’m missing
something here because it would seem far more intuitive to assume that people who are dying are the
most vulnerable of their respective cohorts.
 NoneCompeting Interests:
Reader Comment 02 May 2020
, George Mason University, USADavid Bernstein
I see you have partially addressed this already, but this was going to be my comment: 
Two people who are coded with the same disease could be in vastly different circumstances? We know
the virus has taken a huge toll on nursing homes.  An 82 year old with heart disease who lives in a nursing
home is not similarly-situated, life expectancy-wise, to an 82 year old who is otherwise doing well and is
self-sufficient. The former would assumedly be much more likely to succumb to Covid-19 than the latter.
Similarly, "otherwise-healthy" people who succumb to Covid-19 can be expected to, on average, be more
likely to have an undiagnosed health issue than those who don't. Is that taken into account? If neither of
these are taken into account, the effect on life expectancy must be reduced.
Now, I see you've responded that this should NOT have a major effect on life expectancy. I don't see how
you can be so confident. A *huge* percentage of deaths, wildly disproportionate, have been in nursing
("care") homes. This is an extremely unhealthy population. In the U.S., iirc, the average life expectancy for
someone entering a nursing home is something like 18 months. You simply can't compare an otherwise
healthy 82 year old with heart disease to someone whose heart disease so enfeebles him or her that they
need to be in a nursing home.
 None.Competing Interests:
Author Response 30 Apr 2020
, University of Glasgow, Glasgow, UKDavid McAllister
Thanks for your comment Martin Johnson. Please see this very rapid addendum we posted on our github
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 Thanks for your comment Martin Johnson. Please see this very rapid addendum we posted on our github
repository which I think addresses your comments 
. We will rapidlyhttps://github.com/dmcalli2/covid19_yll_final/blob/master/Scripts/Addendum.md
incorporate these additions into an updated version of the official manuscript as soon as possible.
 No competing interests were disclosed.Competing Interests:
Reader Comment 28 Apr 2020
, ., London, UKMartin Johnson
Useful start to this important question, well done. Given the high correlation of morbidities with COVID-19
deaths (91% with an average of 2.7 pre-existing conditions UK ONS data to March) your conclusion only
one-year reduction in YLL due to comorbidities does not feel correct and warrants further analysis. You list
what I think is a critical factor to determine the impact of comorbidities, ‘did not have markers of underlying
disease severity among those who died’ for example there is a huge difference in YLL for a patient with
Stage 3 or 4 COPD vs Stage 1 or 2. Analysis of care home COVID-19 deaths may assist given that 50% of
those coming into a care home die within 15 months BUPA homes only 
)  both i) those coming to hospital with COVID-19 from a carehttps://eprints.lse.ac.uk/33895/1/dp2769.pdf
home and COVID-19 deaths within a care home (although further complicated by ONS capturing both
death directly from COVID_19 where COVID-19 or suspected COVID-19 was mentioned anywhere on the
death certificate.
Your data set of 701 deaths in Italy is quite small with the rapid increase in UK deaths and the model
established updating the model with a larger data set I believe has some urgency, although ONS together
with Palantir should already have this analysis.
 NoneCompeting Interests:
Author Response 26 Apr 2020
, University of Glasgow, Glasgow, UKDavid McAllister
Davide please see reference 14. Their website is here  . The authors of thehttps://www.epicentro.iss.it/
report at listed at the foot of the link given in reference 14
 No competing interests were disclosed.Competing Interests:
Reader Comment 25 Apr 2020
, Mine, ItalyDavide DeiTos
Sorry, I am not able to find the source, site and organization of the data related death in Italy,
Can you help me? 
Many thanks 
Davide
 No competing interests were disclosed.Competing Interests:
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  No competing interests were disclosed.Competing Interests:
Author Response 25 Apr 2020
, University of Glasgow, Glasgow, UKDavid McAllister
Thanks for these comments.
We agree with Chris Hope that among patients with long term conditions, those with more severe disease
or greater frailty may be at higher risk of dying from COVID19. We have acknowledged this in the
manuscript. However, we would be surprised if this had a large enough effect to result in a substantial
decrement in life expectancy
Thank you to Per Stangeland for his question about the representativeness of the Italian data. According to
the    the report  we based our analysis on defines deaths as "COVID-19Istituto Superiore di Sanità (ISS)
related deaths presented in this report are those occurring in patients who test positive for SARSCoV-2 RT
by PCR, independently from pre-existing diseases" (see 
).https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_26_marzo_eng.pdf
 Author of paper.Competing Interests:
Reader Comment 24 Apr 2020
, Doctor, Cambridge, UKChris Hope
Am I right in thinking that the YLL for each condition, or combination, is taken from the average years of life
that someone with that condition would have left? Have you considered that COVID-19 might be killing the
weakest people with each condition, which would make your estimate too large, possibly greatly so. 
Could you perform a check by asking a random sample of the doctors treating the patients to tell you how
many YLL they think are appropriate for that individual patient?
 NoneCompeting Interests:
Reader Comment 23 Apr 2020
, University of Malaga, SpainPer Stangeland
I’m looking at the age distribution of your sample, from the attached Github file. I’m getting an average age
of 81 for females, 77 for males. Is this correct?
Could you comment on how representative your sample is? There are reports of geriatric care patients
who have not been included in the total death toll in Italy.
 No competing interests were disclosed.Competing Interests:
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